Updates on medical treatment for neuroendocrine neoplasm

Yun LIANG; Shunrong JI; Xianjun YU; Jie CHEN

doi:10.19401/j.cnki.1007-3639.2022.09.001

您当前的位置：

首页 >

文章列表页 >

Updates on medical treatment for neuroendocrine neoplasm

Specialists' Commentary | 更新时间：2025-12-31

- Updates on medical treatment for neuroendocrine neoplasm
- China Oncology Vol. 32, Issue 9, Pages: 757-764(2022)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院神经内分泌肿瘤中心,头颈及神经内分泌肿瘤内科,复旦大学上海医学院肿瘤学系,上海 200032
  2. 复旦大学附属肿瘤医院胰腺外科,复旦大学上海医学院肿瘤学系,复旦大学胰腺肿瘤研究所,上海市胰腺肿瘤研究所,上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.09.001
  CLC： R730.5
- Received：10 July 2022，
  
  Revised：2022-09-01，
  
  Published：30 September 2022
- 稿件说明：
移动端阅览
Yun LIANG, Shunrong JI, Xianjun YU, et al. Updates on medical treatment for neuroendocrine neoplasm[J]. China Oncology, 2022, 32(9): 757-764.
DOI：

Yun LIANG, Shunrong JI, Xianjun YU, et al. Updates on medical treatment for neuroendocrine neoplasm[J]. China Oncology, 2022, 32(9): 757-764. DOI： 10.19401/j.cnki.1007-3639.2022.09.001.

摘要

神经内分泌肿瘤（neuroendocrine neoplasm

NEN）是一类起源于神经内分泌细胞及肽能神经元的高度异质性的少见肿瘤。根据细胞分化的程度

NEN可分为分化好的神经内分泌瘤（neuroendocrine tumor

NET）和分化差的神经内分泌癌（neuroendocrine carcinoma

NEC）。药物治疗是进展期NEN患者首选的全身治疗方式。本文总结了近年来在NEN领域的重要药物临床试验进展

为临床治疗提供参考。

Abstract

Neuroendocrine neoplasm (NEN) is a group of heterogeneous malignancies arising from neuroendocrine cells and peptidergic neurons. According to its cell differentiation

NEN can be divided into two distinct groups as well-differentiated neuroendocrine tumor (NET) and poorly-differentiated neuroendocrine carcinoma (NEC). For advanced NEN

medication is the preferred treatment. In this article

we reviewed current clinical trials in medical treatment for NEN and aimed to provide treatment reference in clinical practice.

关键词

Keywords

references

DASARI A , SHEN C , HALPERIN D , et al . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States [J ] . JAMA Oncol , 2017 , 3 ( 10 ): 1335 - 1342 . DOI: 10.1001/jamaoncol.2017.0589 http://doi.org/10.1001/jamaoncol.2017.0589

WHO Classification of Tumours Editorial Board . WHO classification of tumours of digestive system [M ] . Lyon : IARC Press , 2019 .

WHO Classification of Tumours Editorial Board . Thoracic tumours [M ] . 5th ed. International Agency for Research on Cancer , Lyon, France , 2021 .

CAPLIN M E , PAVEL M , ĆWIKŁA J B , et al . Lanreotide in metastatic enteropancreatic neuroendocrine tumors [J ] . N Engl J Med , 2014 , 371 ( 3 ): 224 - 233 . DOI: 10.1056/NEJMoa1316158 http://doi.org/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158

CAPLIN M E , PAVEL M , PHAN A T , et al . Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study [J ] . Endocrine , 2021 , 71 ( 2 ): 502 - 513 . DOI: 10.1007/s12020-020-02475-2 http://doi.org/10.1007/s12020-020-02475-2

JIMENEZ-FONSECA P , CARMONA-BAYONAS A , LAMARCA A , et al . External validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study [J ] . Neuroendocrinology , 2022 , 112 ( 1 ): 88 - 100 . DOI: 10.1159/000514808 http://doi.org/10.1159/000514808 https://www.karger.com/Article/FullText/514808 https://www.karger.com/Article/FullText/514808

BAUDIN E , HORSCH D , SINGH S , et al . Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase Ⅲ SPINET study [J ] . Ann Oncol , 2021 , 32 : S906 . DOI: 10.1016/j.annonc.2021.08.178 http://doi.org/10.1016/j.annonc.2021.08.178 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023929 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023929

PAVEL M , ĆWIKŁA J B , LOMBARD-BOHAS C , et al . Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results [J ] . Eur J Cancer , 2021 , 157 : 403 - 414 . DOI: 10.1016/j.ejca.2021.06.056 http://doi.org/10.1016/j.ejca.2021.06.056

LEPAGE C , DAHAN L , BOUARIOUA N , et al . Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours [J ] . Dig Liver Dis , 2017 , 49 ( 5 ): 568 - 571 . DOI: 10.1016/j.dld.2017.02.004 http://doi.org/10.1016/j.dld.2017.02.004 https://linkinghub.elsevier.com/retrieve/pii/S1590865817302050 https://linkinghub.elsevier.com/retrieve/pii/S1590865817302050

LEPAGE C , PHELIP J M , LIÈVRE A , et al . Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial [J ] . Ann Oncol , 2020 , 31 : S774 .

LIU Y M , LIU H K , CHEN W C , et al . Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden [J ] . Cancer Med , 2022 , 11 ( 13 ): 2588 - 2600 . DOI: 10.1002/cam4.4628 http://doi.org/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628

FEROLLA P , BRIZZI M P , MEYER T , et al . Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial [J ] . Lancet Oncol , 2017 , 18 ( 12 ): 1652 - 1664 . DOI: S1470-2045(17)30681-2 http://doi.org/S1470-2045(17)30681-2

PAVEL M E , HAINSWORTH J D , BAUDIN E , et al . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study [J ] . Lancet , 2011 , 378 ( 9808 ): 2005 - 2012 . DOI: S0140-6736(11)61742-X http://doi.org/S0140-6736(11)61742-X

RAYMOND E , DAHAN L , RAOUL J L , et al . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [J ] . N Engl J Med , 2011 , 364 ( 6 ): 501 - 513 . DOI: 10.1056/NEJMoa1003825 http://doi.org/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825

XU J M , SHEN L , BAI C M , et al . Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1489 - 1499 . DOI: 10.1016/S1470-2045(20)30493-9 http://doi.org/10.1016/S1470-2045(20)30493-9

LI J , XU J , ZHOU Z , et al . Safety profile and adverse events of special interest for surufatinib in chinese patients with advanced extra-pancreatic neuroendocrine tumors: analysis of the phase 3 SANET-ep trial [J ] . Lung , 2020 , 37 : 4585 - 4598 .

CAPDEVILA J , FAZIO N , LOPEZ LOPEZ C , et al . Final results of the TALENT trial (GETNE1509): a prospective multicohort phase Ⅱ study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs) [J ] . J Clin Oncol , 2019 , 37 (15_suppl): 4106.

CAPDEVILA J , JIMENEZ-VALERIO G , MARTINEZ A , et al . Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: results from the international phase Ⅱ TALENT trial (GETNE 1509) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 4113 . DOI: 10.1200/JCO.2021.39.15_suppl.4113 http://doi.org/10.1200/JCO.2021.39.15_suppl.4113 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4113 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4113

STROSBERG J R , CIVES M , HWANG J , et al . A phase Ⅱ study of axitinib in advanced neuroendocrine tumors [J ] . Endocr Relat Cancer , 2016 , 23 ( 5 ): 411 - 418 . DOI: 10.1530/ERC-16-0008 http://doi.org/10.1530/ERC-16-0008 https://erc.bioscientifica.com/view/journals/erc/23/5/411.xml https://erc.bioscientifica.com/view/journals/erc/23/5/411.xml

LEVY S , VERBEEK W H M , ESKENS F A L M , et al . First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial [J ] . Ther Adv Med Oncol , 2022 , 14 : 17588359221077088.

中国抗癌协会神经内分泌肿瘤专业委员会 . 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版) [J ] . 中国癌症杂志 , 2022 ( 6 ): 545 - 580 .

Society of Neuroendocrine Neoplasm of China Anti-Cancer Association . China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition) [J ] . China Oncol , 2022 ( 6 ): 545 - 580 .

GIROT P , BAUDIN E , SENELLART H , et al . Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French group of endocrine tumors [J ] . Neuroendocrinology , 2022 , 112 ( 6 ): 537 - 546 . DOI: 10.1159/000518650 http://doi.org/10.1159/000518650 https://www.karger.com/Article/FullText/518650 https://www.karger.com/Article/FullText/518650

BUTT B P , STOKMO H L , LADEKARL M , et al . Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas [J ] . Ann Oncol , 2021 , 32 : S915 .

ACOMBE C , PERRIER M , HENTIC O , et al . FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors [J ] . Ann Oncol , 2021 , 32 (suppl_5): S621-S625.

MEHNERT J M , BERGSLAND E , O’NEIL B H , et al . Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study [J ] . Cancer , 2020 , 126 ( 13 ): 3021 - 3030 . DOI: 10.1002/cncr.32883 http://doi.org/10.1002/cncr.32883

STROSBERG J , MIZUNO N , DOI T , et al . Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study [J ] . Clin Cancer Res , 2020 , 26 ( 9 ): 2124 - 2130 . DOI: 10.1158/1078-0432.CCR-19-3014 http://doi.org/10.1158/1078-0432.CCR-19-3014 https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously

LU M , ZHANG P P , ZHANG Y Q , et al . Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase ib trial [J ] . Clin Cancer Res , 2020 , 26 ( 10 ): 2337 - 2345 . DOI: 10.1158/1078-0432.CCR-19-4000 http://doi.org/10.1158/1078-0432.CCR-19-4000

PATEL S P , OTHUS M , CHAE Y K , et al . A phase Ⅱ basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors [J ] . Clin Cancer Res , 2020 , 26 ( 10 ): 2290 - 2296 . DOI: 10.1158/1078-0432.CCR-19-3356 http://doi.org/10.1158/1078-0432.CCR-19-3356 https://aacrjournals.org/clincancerres/article/26/10/2290/82362/A-Phase-II-Basket-Trial-of-Dual-Anti-CTLA-4-and https://aacrjournals.org/clincancerres/article/26/10/2290/82362/A-Phase-II-Basket-Trial-of-Dual-Anti-CTLA-4-and

Thoracique IFdC , Digestive FFdC , Group G-MOC (2019) Nivolumab +/- ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) [EB/OL ] . ( 2020 - 10 - 09 )[ 2022 - 08 - 25 ] . https://clinicaltrials.gov/show/NCT03591731 https://clinicaltrials.gov/show/NCT03591731 https://clinicaltrials.gov/show/NCT03591731 .

CAPDEVILA J , TEULE A , LÓPEZ C , et al . A multi-cohort phase Ⅱ study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601) [J ] . Ann Oncol , 2020 , 31 : S770-S771.

HORN L , MANSFIELD A S , SZCZĘSNA A , et al . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 23 ): 2220 - 2229 . DOI: 10.1056/NEJMoa1809064 http://doi.org/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064

PAZ-ARES L , DVORKIN M , CHEN Y B , et al . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J ] . Lancet , 2019 , 394 ( 10212 ): 1929 - 1939 . DOI: 10.1016/S0140-6736(19)32222-6 http://doi.org/10.1016/S0140-6736(19)32222-6 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226

RIESCO-MARTINEZ M C , CAPDEVILA J , ALONSO V , et al . Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913) [J ] . Ann Oncol , 2021 , 32 : S908 - S909 . DOI: 10.1016/j.annonc.2021.08.180 http://doi.org/10.1016/j.annonc.2021.08.180 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942

HALPERIN D M , LIU S Y , DASARI A , et al . Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial [J ] . JAMA Oncol , 2022 , 8 ( 6 ): 904 - 909 . DOI: 10.1001/jamaoncol.2022.0212 http://doi.org/10.1001/jamaoncol.2022.0212

CAO Y S , LU M , SUN Y , et al . Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial [J ] . J Cancer Res Clin Oncol , 2022 . Online ahead of print.

WHALEN K A , WHITE B H , QUINN J M , et al . Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer [J ] . Mol Cancer Ther , 2019 , 18 ( 11 ): 1926 - 1936 . DOI: 10.1158/1535-7163.MCT-19-0022 http://doi.org/10.1158/1535-7163.MCT-19-0022

SAUNDERS L R , BANKOVICH A J , ANDERSON W C , et al . A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo [J ] . Sci Transl Med , 2015 , 7 ( 302 ): 302 ra136.

DENG S M , YAN X C , LIANG L , et al . The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice [J ] . Biochem Biophys Res Commun , 2017 , 483 ( 1 ): 488 - 494 . DOI: 10.1016/j.bbrc.2016.12.117 http://doi.org/10.1016/j.bbrc.2016.12.117 https://linkinghub.elsevier.com/retrieve/pii/S0006291X16321775 https://linkinghub.elsevier.com/retrieve/pii/S0006291X16321775

HERMANS B C M , DERKS J L , THUNNISSEN E , et al . DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile [J ] . Lung Cancer , 2019 , 138 : 102 - 108 . DOI: S0169-5002(19)30680-4 http://doi.org/S0169-5002(19)30680-4

MATSUO K , TANIGUCHI K , HAMAMOTO H , et al . Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy [J ] . Cancer Sci , 2019 , 110 ( 10 ): 3122 - 3131 . DOI: 10.1111/cas.14157 http://doi.org/10.1111/cas.14157 https://onlinelibrary.wiley.com/doi/10.1111/cas.14157 https://onlinelibrary.wiley.com/doi/10.1111/cas.14157

RUDIN C M , PIETANZA M C , BAUER T M , et al . Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study [J ] . Lancet Oncol , 2017 , 18 ( 1 ): 42 - 51 . DOI: S1470-2045(16)30565-4 http://doi.org/S1470-2045(16)30565-4

MORGENSZTERN D , BESSE B , GREILLIER L , et al . Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase Ⅱ TRINITY study [J ] . Clin Cancer Res , 2019 , 25 ( 23 ): 6958 - 6966 . DOI: 10.1158/1078-0432.CCR-19-1133 http://doi.org/10.1158/1078-0432.CCR-19-1133 https://aacrjournals.org/clincancerres/article/25/23/6958/82239/Efficacy-and-Safety-of-Rovalpituzumab-Tesirine-in https://aacrjournals.org/clincancerres/article/25/23/6958/82239/Efficacy-and-Safety-of-Rovalpituzumab-Tesirine-in

MORGENSZTERN D , JOHNSON M , RUDIN C M , et al . SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study [J ] . Lung Cancer , 2020 , 145 : 126 - 131 . DOI: S0169-5002(20)30387-1 http://doi.org/S0169-5002(20)30387-1

MIYAGAWA-HAYASHINO A , OKADA S , TAKEDA-MIYATA N , et al . TTF-1 and c-MYC-defined phenotypes of large cell neuroendocrine carcinoma and delta-like protein 3 expression for treatment selection [J ] . Appl Immunohistochem Mol Morphol , 2021 , 29 ( 4 ): 313 - 320 . DOI: 10.1097/PAI.0000000000000875 http://doi.org/10.1097/PAI.0000000000000875 https://journals.lww.com/10.1097/PAI.0000000000000875 https://journals.lww.com/10.1097/PAI.0000000000000875

THOMAS A , TAKAHASHI N , RAJAPAKSE V N , et al . Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress [J ] . Cancer Cell , 2021 , 39 ( 4 ): 566 - 579 .e7. DOI: 10.1016/j.ccell.2021.02.014 http://doi.org/10.1016/j.ccell.2021.02.014

JONASCH E , DONSKOV F , ILIOPOULOS O , et al . Belzutifan for renal cell carcinoma in von hippel-lindau disease [J ] . N Engl J Med , 2021 , 385 ( 22 ): 2036 - 2046 . DOI: 10.1056/NEJMoa2103425 http://doi.org/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425

KLEMPNER S J , GERSHENHORN B , TRAN P , et al . BRAF V600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy [J ] . Cancer Discov , 2016 , 6 ( 6 ): 594 - 600 . DOI: 10.1158/2159-8290.CD-15-1192 http://doi.org/10.1158/2159-8290.CD-15-1192

IDREES K , PADMANABHAN C , LIU E , et al . Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma [J ] . J Surg Oncol , 2018 , 117 ( 2 ): 284 - 289 . DOI: 10.1002/jso.24834 http://doi.org/10.1002/jso.24834 https://onlinelibrary.wiley.com/doi/10.1002/jso.24834 https://onlinelibrary.wiley.com/doi/10.1002/jso.24834

CAPDEVILA J , ARQUÉS O , HERNÁNDEZ MORA J R , et al . Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAF V600E blockade in col on neuroendocrine carcinomas [J ] . Clin Cancer Res , 2020 , 26 ( 4 ): 902 - 909 . DOI: 10.1158/1078-0432.CCR-19-1266 http://doi.org/10.1158/1078-0432.CCR-19-1266 https://aacrjournals.org/clincancerres/article/26/4/902/83196/Epigenetic-EGFR-Gene-Repression-Confers https://aacrjournals.org/clincancerres/article/26/4/902/83196/Epigenetic-EGFR-Gene-Repression-Confers

BURKART J , OWEN D , SHAH M H , et al . Targeting BRAF mutations in high-grade neuroendocrine carcinoma of the colon [J ] . J Natl Compr Canc Netw , 2018 , 16 ( 9 ): 1035 - 1040 . DOI: 10.6004/jnccn.2018.7043 http://doi.org/10.6004/jnccn.2018.7043 https://jnccn.org/doi/10.6004/jnccn.2018.7043 https://jnccn.org/doi/10.6004/jnccn.2018.7043

Views

3389

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress of important clinical research on breast cancer in China in 2024

China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)

Epidemiology and clinicopathological characteristics analysis of 279 neuroendocrine neoplasms cases in Dalian

Progress of important clinical research on breast cancer in China in 2025

Related Author

Xin YANG

Qianfeng SHI

Qiang LIU

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society

玄基泽

陈丹

时畅

温志红

Related Institution

Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

大连医科大学附属第一医院病理科

大连市第五人民医院放射线科

Department of Breast Surgery, the First Affiliated Hospital of China Medical University

AI问答

⁰